Aryeh Jason's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Jun 12, 2026
- Accession no.
- 0002001011-26-000103
- Filed
- Jun 12, 2026
- Trade date
- Jun 5-11, 2026
- Filing delay
- 7 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.25M. It was filed 7 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Aryeh JasonCIK 0001376960 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Common Stock | AGrant or awardAcquired | +836 | $0.00 | $0 | 107,580 | Direct | |
| Jun 10, 2026 | Common Stock | SSaleDisposed | −500 | $250.00 | −$125,000 | 107,080 | Direct | |
| Jun 11, 2026 | Common Stock | SSaleDisposed | −4,500 | $250.00 | −$1,125,000 | 102,580 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 5, 2026 | Common Stock | AGrant or awardAcquired | +2,938 | $0.00 | $0 | 2,938 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.